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Autoantibodies in Moroccan patients with 
type 1 diabetes: Which one to choose? 
AbstrAct
background. Immunological investigations are intend-
ed for diagnosing t1D in atypical clinical presentation, 
also exploring the predisposition to t1D in a context of 
multiple autoimmune disorders or among the siblings 
of a patient with type 1 diabetes. While the diagnosing 
or the screening of T1D using five antibodies presents 
high expenses especially in emerging countries, it is 
for interest to determine their prevalence in order to 
choose the most frequent and most relevant. the aim 
of our study is to determine the prevalence of antibod-
ies in Moroccan population. 
Methods. We investigated 62 t1D patients, the preva-
lence of autoantibodies was 74% for glutamic acid 
decarboxylase 65 auto-antibody (GADA), 46% for 
insulinoma-associated protein 2 autoantibody (IA2A), 
and 3% for islet cell antibodies (IcA). GADA and/or 
IA2A were reported in all patients (100%). the GADA 
frequency was neither associated with the duration of 
diabetes nor the age of patients. 
results. Finally, GADAs are by far the best markers 
for t1D, IA2As complements GADAs and increases 
the diagnostic sensitivity for detection of pancreatic 
autoimmunity and IcA should be abandoned because 
of its low prevalence. (clin Diabetol 2021; 10)
Key words: Moroccan type 1 diabetes, pancreatic 
autoimmunity, pancreatic autoantibodies, GADA, 
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Introduction
Type 1 diabetes (T1D) is the result of a destructive 
inflammatory process of the pancreatic b cells and 
the final consequence is insulinopenia noting that 
pancreatic antibodies (Ab) are considered markers 
and not actors of this cell destruction. The antibodies 
test is important to make an etiological diagnosis of 
diabetes in atypical clinical presentation, moreover, 
to study the predisposition in first-degree family 
members of a patient with T1D and in a context of 
multi-organ autoimmunity. There are five types of anti-
pancreatic antibodies: glutamic acid decarboxylase 65 
auto-antibody (GADA), insulinoma-associated protein 
2 autoantibody (IA2A), islet cell antibodies (ICA), insu-
lin autoantibodies (IAA) and recently Zinc Transporter 
8 antibody (ZnT8A). Given the high cost of the five 
antibodies, especially in emerging countries, our study 
aspires to provide evidence about their prevalence in 
Moroccan T1D and therefore to choose the most fre-
quent and most relevant one.
Materials and methods
A cross-sectional study of patients with T1DM was 
conducted in the endocrinology department of Moulay 
Ismail military hospital in Meknes, Morocco, for the 
period extending from January 2016 to June 2019. All 
T1D patients were included. We collected demographic 
parameters (age, sex, age of discovery and duration 
of diabetes) and serological parameters (GADA, IA2A 
and ICA) which were analyzed using an electrochemi-
luminescence technique on the standardized fully au-
tomated MAGLUMI CLIA analyzer. ZnT8A has not been 
performed because it is not available and IAA has not 
been performed because patients are not insulin naive. 
An exclusion criteria for this study was the absence of 
laboratory confirmation of autoimmunity (negative im-
munoassay). The study was approved by their local ethics 
committees and all patients gave informed consent.
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Statistical analysis was performed with SPSS 
(Statistical Package for the Social Sciences) version 
23 statistic software package. Data were expressed 
as means ± standard deviation (SD). Comparisons 
between groups were performed with analysis of non-
parametric test. A value of P < 0.05 was considered 
statistically significant.
Results
A total of 62 patients, 47 men and 15 women were 
included, after excluding 10 patients with negative 
pancreatic autoimmunity. The mean age at diagnosis 
was 17 years and the mean duration of diabetes was 
8 years. The prevalence of Ab was 74% for GADA, 42% 
for IA2 and only 3% for ICA. GADA and/or IA2A were 
reported in all patients (100%). Table 1 and Figure 1 
show distribution of all autoantibodies.
We analyzed the prevalence of autoantibodies at 
different ages at diagnosis, in the adult population 
(46/62), 32 patients had GADA (70%) and 19 patients 
had IA2A (41%), while in children (16/62), we found 14 
cases with GADA (88%) and 7 cases with IA2A (44%). 
Table 2 summarizes the distribution of auto-antibodies 
by age. The mean duration of diabetes was 8 years (0 to 
32 years), and we chose two groups of T1D to analyze 
the association between prevalence of antibodies and 
diabetes duration. In the 26 recent diabetes patients 
(disease duration ≤ 1 year), GADA were present in 22 
cases (85%) and 10 cases for IA2A (38%), while in the 
36 patients with long duration of diabetes (> 1 ans), 
24 had GADA (67%) and 16 had IA2A (44%) (Table 3). 
Increased frequency of antibodies was not associated 
with younger age or recent diabetes
Discussion
Pancreatic autoantibodies are used in current 
diabetology practice to make an etiological diagnosis 
of diabetes in an atypical clinical presentation, as well 
table 1. Demography and autoantibodies of patients with t1D
cases sex (M/F) Age at diagnosis 
[years] (mean) 
range
Duration of diabetes 
[years] 
range
GADA IA2A IcA GADA and/or  
IA2A




46/62 26/62 2/62 62/62






GADA + IA2A 13%
GADA + IA2A + ICA 3%
GADA alone 58%
Autoantibodies in Moroccan patients with Type 1 diabetes
Figure 1. The distribution of autoantibodies in Moroccan patients with type 1 diabetes. Abs — antibodies; GADA — glutamic 
acid decarboxylase; IA2A — insulinoma-associated protein 2 autoantibody; ICA — islet cell antibodies
table 2. Prevalence of autoantibodies according to age at diagnosis of t1D
Frequency of antibodies group GADA IA2A IcA GADA and/or IA2A
Children 88% 44% 6% 100%
(16/62) (14/16) (7/16) (1/16) (16/16)
Adults 70% 41% 2% 100%
(46/62) (32/46) (19/46) (1/46) (46/46)
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as to define the predisposition of T1D in first-degree 
family members of a patient with T1D. There are five 
types of anti-pancreatic antibodies: GADA, IA2A, ICA, 
IAA and ZnT8A. We did not test the IAA in our study due 
to the fact that most of the patients were already on 
insulin therapy neither was ZnT8 since it is not available 
in our platform [1]. To our knowledge the frequency 
of these CAs has not been evaluated in the Moroccan 
or North African population, hence the interest of this 
study. GADAs autoantibody is present in approximately 
60 to 80% in all the populations studied of T1D, they 
were considered to be the best marker of pancreatic 
autoimmunity. Overall the GADA prevalence in our 
series (74%) was consistent with that reported in the 
Caucasian population (60-80%). In the Asian popula-
tion they are the most represented but with a lower 
prevalence (30–47%) [2, 3].
In our study, GADA prevalence was higher in chil-
dren and adolescents compared to adults (88% versus 
68%) and most studies share the same finding [4–6]. 
However, increased frequency was not statistically as-
sociated with younger age in our study and a minority 
of authors have reported that age does not affect the 
test results [3, 7]. 
By analyzing diabetes duration and antibodies 
prevalence, we have demonstrated that the detection 
sensitivity of GADA is very high at 85% in the pres-
ence of recent diabetes against 67% for long duration 
diabetes. Considering the spread of our population 
according to the diabetes duration (8 years on aver-
age and 8 years of standard deviation), we observed 
a perfect agreement with the opinion who said that 
GADA declines more slowly [2, 3, 8].
IA2As were present in 50 to 80% of T1D within one 
year after diagnosis in Caucasian populations whereas 
they are considered to be weak markers in Asian popu-
lation (< 40%) which is similar to our results (38%). 
This low prevalence is not modifiable regardless of the 
diabetes duration or the younger age [3, 8, 9]. 
The real surprise in our population is that we still 
have near zero prevalence of ICA, while it is around 
50% in some series [3, 10] So we think that the ICA 
test should be abandoned in our context.
Limitations
The main limitation of our monocentric study is the 
small sample size and large age spread of our popula-
tion study. Further multicenter studies should be carried 
and focus on the measurement of ZnT8A.
Conclusion
The prevalence of GADA or IA2A varies in different 
ethnicities. This is the first study that examined the 
prevalence of anti-pancreatic antibodies in Moroccan 
population. In our population GADAs are by far the 
best markers for T1D diagnosis, and even though the 
IA2As are considered weak tests in comparison with 
GADA they are still a second choice test, they increase 
the detection sensitivity. We think that ICA should be 
abandoned because of its low prevalence. Finally, we 
are impatiently awaiting for the availability of ZnT8A 
in our platform to be able to compare them with other 
pancreatic autoantibodies.
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